LG-912

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLG-912
Drug Alias NameE1/E2-expressing lentiviral vector-based gene therapy (Lentigen)E1/E2-expressing lentiviral vector-based gene therapy (Lentigen/Epixis)LG-912
ClassificationVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineBiologics > Protein drugs > Recombinant proteinVaccines > Application > Therapeutic vaccine
Mechanisms of ActionEnvelope glycoprotein modulators
TargetsEnvelope glycoprotein
Therapy Area/IndicationsLiver NeoplasmsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLentigen Technology Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVbi Vaccines IncEpixisLentigen Technology Inc
Active IndicationsN/A
Inactive IndicationsLiver NeoplasmsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A